Moreover, we found that SMAD5 expression levels had independent prognostic value in stratifying patients with Stage 3 and 4 CRC into high‐risk and low‐risk groups (p = 0.046; supplementary material, Figure 2C). The gene discussed is SMAD5; the disease is colorectal carcinoma.